Glucagon-like peptide-1 receptor agonists (GLP-1s), such as Ozempic and Mounjaro, have become popular medications for controlling diabetes and treating obesity but new Canadian research suggests they can also lead to a paradoxical side effect in the form of eye problems
The Phase 2 retatrutide trial showed that participants who combined the drug with lifestyle intervention maintained more muscle mass and had better metabolic markers than those who relied on the drug alone
Rather than pushing through exhaustion, evidence-based guidance supports adjusting intensity, protecting sleep, fueling adequately, and maintaining consistent but manageable movement
Risks, side effects and practical cautions Across peptide classes, the main risk domains are: Pharmacologic side effects
Compounded formulations are prepared by licensed pharmacies using pharmaceutical-grade active ingredients under quality standards, but without that branded trial portfolio
Yes, SIBO and SIFO may be the underlying issue